NCT03785873 2026-02-13Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract CancerUniversity of Michigan Rogel Cancer CenterPhase 1/2 Completed34 enrolled 13 charts